Hannah Cheeseman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1937625/publications.pdf

Version: 2024-02-01

		932766	1372195	
10	720	10	10	
papers	citations	h-index	g-index	
11	11	11	1395	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Vaccines for COVID-19. Clinical and Experimental Immunology, 2020, 202, 162-192.	1.1	185
2	In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. PLoS ONE, 2011, 6, e19252.	1.1	160
3	Airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunology, 2018, 11, 249-256.	2.7	85
4	Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIVâ€1 Vaccine Candidates. Journal of Infectious Diseases, 2010, 201, 720-729.	1.9	74
5	A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2012, 7, e41936.	1.1	74
6	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. BMJ, The, 2021, 372, n423.	3.0	56
7	A DNA-Based Candidate HIV Vaccine Delivered via <i>In Vivo</i> Electroporation Induces CD4 Responses toward the α4β7-Binding V2 Loop of HIV gp120 in Healthy Volunteers. Vaccine Journal, 2012, 19, 1557-1559.	3.2	36
8	Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults. Vaccine Journal, 2013, 20, 397-408.	3.2	23
9	Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials. Journal of Immunological Methods, 2011, 370, 43-54.	0.6	14
10	Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2014, 9, e90378.	1.1	13